Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map

IMPORTANCE: Limited data exist on the real-world safety outcomes of patients with neovascular age-related macular degeneration treated with brolucizumab (Beovu). OBJECTIVE: To determine the real-world incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and/or retinal vascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M., Zarbin, Marco A., Barakat, Mark R., Albini, Thomas A., Kaiser, Peter K., B, Guruprasad, Agashivala, Neetu, Yu, Justin S., Wykoff, Charles C., MacCumber, Mathew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613703/
https://www.ncbi.nlm.nih.gov/pubmed/34817566
http://dx.doi.org/10.1001/jamaophthalmol.2021.4585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613703/
https://www.ncbi.nlm.nih.gov/pubmed/34817566
http://dx.doi.org/10.1001/jamaophthalmol.2021.4585

Ejemplares similares